Allelic strengths of encephalopathy-associated UBA5 variants correlate between in vivo and in vitro assays
eLife · 11.12.2023 · 12
DOI: 10.7554/elife.89891.3 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 11.12.2023. Verfasst von Xueyang Pan und 12 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Office of Research Infrastructure Programs, National Institutes of Health, Huffington Foundation, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Protein UFMylation downstream of the E1 enzyme UBA5 plays essential roles in development and endoplasmic reticulum stress. Variants in the UBA5 gene are associated with developmental and epileptic encephalopathy 44 (DEE44), an autosomal recessive disorder characterized by early-onset encephalopathy, movement abnormalities, global developmental delay, intellectual disability, and seizures. DEE44 is caused by at least 12 different missense variants described as loss of function (LoF), but the relationships between genotypes and molecular or clinical phenotypes remain to be established. We developed a humanized UBA5 fly model and biochemical activity assays in order to describe in vivo and in vitro genotype–phenotype relationships across the UBA5 allelic series. In vivo, we observed a broad spectrum of phenotypes in viability, developmental timing, lifespan, locomotor activity, and bang sensitivity. A range of functional effects was also observed in vitro across comprehensive biochemical assays for protein stability, ATP binding, UFM1 activation, and UFM1 transthiolation. Importantly, there is a strong correlation between in vivo and in vitro phenotypes, establishing a classification of LoF variants into mild, intermediate, and severe allelic strengths. By systemically evaluating UBA5 variants across in vivo and in vitro platforms, this study provides a foundation for more basic and translational UBA5 research, as well as a basis for evaluating current and future individuals afflicted with this rare disease.
Förderung
- Office of Research Infrastructure Programs, National Institutes of Health
- Huffington Foundation
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- OHSU Molecular Microbiology and Immunology Interdisciplinary Pilot Award
- National Center for Advancing Translational Sciences
- National Institute of General Medical Sciences
- U.S. Department of Veterans Affairs
- Office of Strategic Coordination
Zitieren
APA
Pan, X., Alvarez, A. N., Ma, M., Lu, S., Crawford, M. W., Briere, L. C., Kanca, O., Yamamoto, S., Sweetser, D. A., Wilson, J. L., Napier, R. J., Pruneda, J. N., & Bellen, H. J. (2023). Allelic strengths of encephalopathy-associated UBA5 variants correlate between in vivo and in vitro assays. eLife, 12. https://doi.org/10.7554/elife.89891.3
Vancouver
Pan X, Alvarez AN, Ma M, Lu S, Crawford MW, Briere LC, et al. Allelic strengths of encephalopathy-associated UBA5 variants correlate between in vivo and in vitro assays. eLife. 2023;12. doi:10.7554/elife.89891.3
BibTeX
@article{Pan2023,
author = {Pan, Xueyang and Alvarez, Albert N and Ma, Mengqi and Lu, Shenzhao and Crawford, Michael W and Briere, Lauren C and Kanca, Oguz and Yamamoto, Shinya and Sweetser, David A and Wilson, Jenny L and Napier, Ruth J and Pruneda, Jonathan N and Bellen, Hugo J},
title = {Allelic strengths of encephalopathy-associated UBA5 variants correlate between in vivo and in vitro assays},
journal = {eLife},
year = {2023},
volume = {12},
doi = {10.7554/elife.89891.3}
}
EUVIMED